Silver Book Fact

In one study, deep-brain stimulation for Parkinson’s patients significantly reduced their required dosages of antiparkinsonian medications, consequently decreasing their medication costs by 32% 1 year after surgery, and 39% 2 years after.

Charles, P. David, Bimal P. Padaliya, William J. Newman, Chadler E. Gill, Cassondra D. Covington, John F. Yang, Stephanie A. So, Michael G. Tramontana, Peter E. Kondrad, and Thomas L. Davis. Deep Brain Stimulation of the Subthalamic Nucleus Reduces Antiparkinsonian Medication Costs. Parkinsonism & Related Disorders. 2004; 10(8): 475-9. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=15542007&dopt=AbstractPlus

Reference

Title
Deep Brain Stimulation of the Subthalamic Nucleus Reduces Antiparkinsonian Medication Costs
Publication
Parkinsonism & Related Disorders
Publication Date
2004
Authors
Charles, P. David, Bimal P. Padaliya, William J. Newman, Chadler E. Gill, Cassondra D. Covington, John F. Yang, Stephanie A. So, Michael G. Tramontana, Peter E. Kondrad, and Thomas L. Davis
Volume & Issue
Volume 10, Issue 8
Pages
475-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Out-of-Pocket Costs, 5-Year Delayed Onset  
  • A $1 billion-investment in Alzheimer’s research that led to research breakthroughs by 2010 could have a 10-to-1 return by 2015, and a 90-to-1 return by 2050.  
  • A large set of NIH clinical trials are assessing interventions (including dietary supplements–creatine and coenzyme Q10) that may slow the progression of Parkinson’s disease.  
  • According to the Pharmaceutical Research and Manufacturers of America, one of the most promising medicines in development uses normal human cells to enhance brain levels of dopamine, the neurotransmitter deficient…  
  • Use of existing or new drugs/compounds for Alzheimer’s prevention could result in a delay of onset of between 2 and 5 years.